Potential survival gains in the treatment of myocardial infarction
Key result
Better application of secondary prevention treatments provided greater absolute survival gains (104 lives/10,000 by 12 months) compared to a putative novel treatment (4 lives/10,000).
Why the study?
Does complete implementation of guideline recommendations improve mortality and recurrent MI or stroke in patients with MI compared to observed utilization rates and putative novel treatments?
Population
1630 patients with myocardial infarction from a nationwide registry, adjusted for age, gender and GRACE…
Comparison
Complete implementation of guideline-recommended… vs Observed guideline recommendation utilisation…
Design
Other
Follow-up
up to 12 months
Authors
Discussion
Loading...
Member takes
Implication
Prioritizing adherence to secondary prevention may maximize gains; hypothesis-generating for implementation versus novel therapies in MI registries.
Structured PICO
Does complete implementation of guideline recommendations improve mortality and recurrent MI or stroke in patients with MI compared to observed utilization rates and putative novel treatments?
P
Population
1630 patients with myocardial infarction from a nationwide registry, adjusted for age, gender and GRACE score, extrapolated to a population of 10,000 patients
I
Intervention
Complete implementation of guideline-recommended treatments and a putative novel treatment providing a 10-30% 12-month event reduction
C
Comparator
Observed guideline recommendation utilisation rates
O
Outcome
Mortality and recurrent MI or stroke by 30 days and 30 days to 12 monthshard clinical
Improving adherence to existing guideline-recommended secondary prevention treatments in MI care offers substantially greater potential survival gains than introducing novel therapies.
Cite This Study
Chew et al. (2009) studied Myocardial infarction (n=1,630). Complete implementation of guideline recommendations vs. Putative novel treatment was evaluated on Mortality and recurrent MI or stroke by 30 days and 30 days to 12 months. Better application of secondary prevention treatments provided greater absolute survival gains (104 lives/10,000 by 12 months) compared to a putative novel treatment (4 lives/10,000).